422 related articles for article (PubMed ID: 35710164)
1. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Alami F; Alizadeh M; Shateri K
Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
[TBL] [Abstract][Full Text] [Related]
2. Dietary approaches to stop hypertension (DASH) diet improves hepatic fibrosis, steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Sangouni AA; Nadjarzadeh A; Rohani FS; Sharuni F; Zare Z; Rahimpour S; Hojjat H; Hosseinzadeh M
Eur J Nutr; 2024 Feb; 63(1):95-105. PubMed ID: 37855891
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
Front Immunol; 2022; 13():949746. PubMed ID: 36159792
[TBL] [Abstract][Full Text] [Related]
4. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.
Rusu E; Jinga M; Enache G; Rusu F; Dragomir AD; Ancuta I; Draguţ R; Parpala C; Nan R; Sima I; Ateia S; Stoica V; Cheţa DM; Radulian G
Nutr J; 2013 Aug; 12():119. PubMed ID: 23941362
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Panahi Y; Ghamarchehreh ME; Beiraghdar F; Zare R; Jalalian HR; Sahebkar A
Hepatogastroenterology; 2012 Oct; 59(119):2099-2103. PubMed ID: 23234816
[TBL] [Abstract][Full Text] [Related]
6. Associations of physical activity and fitness with hepatic steatosis, liver enzymes, and insulin resistance in children with overweight/obesity.
Medrano M; Arenaza L; Migueles JH; Rodríguez-Vigil B; Ruiz JR; Labayen I
Pediatr Diabetes; 2020 Jun; 21(4):565-574. PubMed ID: 32237015
[TBL] [Abstract][Full Text] [Related]
7. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats.
Al Zarzour RH; Ahmad M; Asmawi MZ; Kaur G; Saeed MAA; Al-Mansoub MA; Saghir SAM; Usman NS; Al-Dulaimi DW; Yam MF
Nutrients; 2017 Jul; 9(7):. PubMed ID: 28718838
[TBL] [Abstract][Full Text] [Related]
8. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease.
Zhang J; Li S; Li J; Han C; Wang Z; Li C; Wang X; Liu Z; Wen J; Zheng L
Chin Med J (Engl); 2014; 127(21):3771-6. PubMed ID: 25382334
[TBL] [Abstract][Full Text] [Related]
9. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
[TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease.
Sheng X; Che H; Ji Q; Yang F; Lv J; Wang Y; Xian H; Wang L
Horm Metab Res; 2018 May; 50(5):397-402. PubMed ID: 29723898
[TBL] [Abstract][Full Text] [Related]
11. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
12. Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction.
Krawczyk M; Maciejewska D; Ryterska K; Czerwińka-Rogowska M; Jamioł-Milc D; Skonieczna-Żydecka K; Milkiewicz P; Raszeja-Wyszomirska J; Stachowska E
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453660
[TBL] [Abstract][Full Text] [Related]
13. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
[TBL] [Abstract][Full Text] [Related]
14. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial.
Darvish Damavandi R; Shidfar F; Najafi M; Janani L; Masoodi M; Akbari-Fakhrabadi M; Dehnad A
Phytother Res; 2021 Jun; 35(6):3145-3156. PubMed ID: 33880813
[TBL] [Abstract][Full Text] [Related]
15. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
16. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
[TBL] [Abstract][Full Text] [Related]
17. The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Ghanbari P; Raiesi D; Alboebadi R; Zarejavid A; Dianati M; Razmi H; Bazyar H
BMC Complement Med Ther; 2024 May; 24(1):192. PubMed ID: 38755622
[TBL] [Abstract][Full Text] [Related]
18. Association of adiponectin with hepatic steatosis: a study of 1,349 subjects in a random population sample.
Flechtner-Mors M; George SN; Oeztuerk S; Haenle MM; Koenig W; Imhof A; Boehm BO; Graeter T; Mason RA; Kratzer W; Akinli AS;
BMC Res Notes; 2014 Apr; 7():207. PubMed ID: 24693952
[TBL] [Abstract][Full Text] [Related]
19. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
20. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents.
Chin J; Mori TA; Adams LA; Beilin LJ; Huang RC; Olynyk JK; Ayonrinde OT
JHEP Rep; 2020 Dec; 2(6):100150. PubMed ID: 32984791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
